Wolpert, Elisabeth Z.
Norman, Sara
Eek, Daniel http://orcid.org/0000-0002-6610-4369
Holmesson, Carina
Fernström, Anders
Article History
Received: 25 October 2022
Accepted: 10 May 2023
First Online: 9 June 2023
Declarations
:
: The study was approved by the Swedish Ethical Review Authority (reference number 2021-01968).
: All patients provided informed consent to participate in the study.
: Not applicable.
: Elisabeth Z. Wolpert has a minor consultancy position with AstraZeneca. Sara Norman is a full-time employee at the Swedish Kidney Association, which received a minor, financial compensation from AstraZeneca for patient recruitment. Daniel Eek is a full-time employee of the study sponsor AstraZeneca and owns stock in the company. Carina Holmesson reports no conflicts of interest. Anders Fernström reports consulting fees from Vifor Pharma, Alnylam, and AstraZeneca; payment/honoraria for lectures, presentations or educational events from Otsuka; and participation on an advisory board for Vifor Pharma and AstraZeneca.